Recent update on future therapeutic strategies for COVID-19 vaccination with omicron variant

IF 0.5 Q4 GENETICS & HEREDITY Human Gene Pub Date : 2024-03-24 DOI:10.1016/j.humgen.2024.201281
Doha El-Sayed Ellakwa , Abdelkarim Farag Elsheikh-Hassan , Takwa E. Ellakwa , Mohamed Ahmed Abdelmalek
{"title":"Recent update on future therapeutic strategies for COVID-19 vaccination with omicron variant","authors":"Doha El-Sayed Ellakwa ,&nbsp;Abdelkarim Farag Elsheikh-Hassan ,&nbsp;Takwa E. Ellakwa ,&nbsp;Mohamed Ahmed Abdelmalek","doi":"10.1016/j.humgen.2024.201281","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>The zoonotic infection known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease 19 (COVID-19) pandemic and a public health hazard. This virus outbreak has infected people from all around the world. The Omicron variant has become the most transmissible and immune-evasive form of SARS-CoV-2 with numerous mutations. The Omicron variant has sparked international concern and has become the dominant variant in multiple regions. The globe is scrambling to find and develop coronavirus disease vaccinations to be protected during this war. Vaccine phobia is one of the most significant barriers to global health. This review emphasizes the continual improvements in the conception and creation of various vaccination platforms. These compositions, difficulties, restrictions, and the mechanism of action are also covered. Additionally, the efficiency of the top vaccination candidates against all dangerous SARS-CoV-2 mutations is emphasized.</p></div><div><h3>Results</h3><p>This new disease is pressuring scientists to find a safe and effective vaccination as soon as possible. This review indicates a global effort by scientists and businesses to attain one of the century's most challenging goals.</p></div><div><h3>Conclusions</h3><p>The COVID-19 vaccine differs in approaches and technologies that are used in developing it, which affects its overall effectiveness and side effects, and that can lead us to select the proper vaccine for a suitable case with the best route of administration.</p></div>","PeriodicalId":29686,"journal":{"name":"Human Gene","volume":"40 ","pages":"Article 201281"},"PeriodicalIF":0.5000,"publicationDate":"2024-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Gene","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2773044124000251","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

The zoonotic infection known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease 19 (COVID-19) pandemic and a public health hazard. This virus outbreak has infected people from all around the world. The Omicron variant has become the most transmissible and immune-evasive form of SARS-CoV-2 with numerous mutations. The Omicron variant has sparked international concern and has become the dominant variant in multiple regions. The globe is scrambling to find and develop coronavirus disease vaccinations to be protected during this war. Vaccine phobia is one of the most significant barriers to global health. This review emphasizes the continual improvements in the conception and creation of various vaccination platforms. These compositions, difficulties, restrictions, and the mechanism of action are also covered. Additionally, the efficiency of the top vaccination candidates against all dangerous SARS-CoV-2 mutations is emphasized.

Results

This new disease is pressuring scientists to find a safe and effective vaccination as soon as possible. This review indicates a global effort by scientists and businesses to attain one of the century's most challenging goals.

Conclusions

The COVID-19 vaccine differs in approaches and technologies that are used in developing it, which affects its overall effectiveness and side effects, and that can lead us to select the proper vaccine for a suitable case with the best route of administration.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
关于 COVID-19 奥米克变体疫苗未来治疗策略的最新进展
背景被称为严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)的人畜共患传染病是冠状病毒病 19(COVID-19)大流行的原因,也是对公共健康的危害。这一病毒的爆发感染了世界各地的人们。Omicron 变体已成为 SARS-CoV-2 中最易传播和最具免疫侵袭性的形式,并发生了多次变异。Omicron 变体引发了国际关注,并已成为多个地区的主要变体。全球都在争先恐后地寻找和开发冠状病毒疾病疫苗,以便在这场战争中得到保护。疫苗恐惧症是全球健康的最大障碍之一。本综述强调了各种疫苗接种平台在构思和创建过程中的不断改进。其中还包括这些成分、困难、限制和作用机制。此外,还强调了候选的顶级疫苗对所有危险的 SARS-CoV-2 变异的有效性。结论 COVID-19 疫苗在开发方法和技术上存在差异,这影响了疫苗的整体效果和副作用,并可能导致我们以最佳的给药途径为合适的病例选择合适的疫苗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Human Gene
Human Gene Biochemistry, Genetics and Molecular Biology (General), Genetics
CiteScore
1.60
自引率
0.00%
发文量
0
审稿时长
54 days
期刊最新文献
Exploring the relationship between ERCC1 polymorphisms and colorectal cancer risk: Insights from an in-depth meta-analysis Solute carrier family 2 members (SLC2A) as potential targets for the treatment of head and neck squamous cell carcinoma patients Meta-analysis of genes and genetic variants implicated in Type II diabetes mellitus, diabetic retinopathy, and diabetic nephropathy Network pharmacology and molecular docking insights into Sirtuin-2 inhibitors (AK-7 and AGK-2): A synergistic strategy for COPD treatment β2_adrenergic receptor gene polymorphisms p.Gly16Arg and p. Glu27Gln in Sudanese patients with bronchial asthma: A case-control study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1